Immunology and Biotherapies
11.9K views | +14 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Side effects of Immune System Drugs: Cytokines and Monoclonal Antibodies

Side effects of Immune System Drugs: Cytokines and Monoclonal Antibodies | Immunology and Biotherapies | Scoop.it
Abstract

This review of the July 2013 to December 2014 publications on cytokines and monoclonal antibodies covers bone morphogenic proteins, colony-stimulating factors, interferons, interleukins, tumor necrosis factor alfa, adalimumab, certolizumab, etanercept, golimumab, infliximab, abciximab, alemtuzumab, bevacizumab, cetuximab, daclizumab, natalizumab, ranibizumab, rituximab, tocilizumab and trastuzumab.

 

KeywordsAdverse reactions; Cytokines; Monoclonal antibodies; Bone morphogenic proteins;Colony-stimulating factors; Interferons; Interleukins; Tumor necrosis factor alfa;Adalimumab; Certolizumab; Etanercept; Golimumab; Infliximab; Abciximab;Alemtuzumab; Bevacizumab; Cetuximab; Daclizumab; Natalizumab; Ranibizumab;Rituximab; Tocilizumab; Trastuzumab


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, October 10, 2015 1:43 PM
Side Effects of Drugs Annual

Available online 1 October 2015

In Press, Corrected Proof — Note to users

 
Drugs That Act on the Immune System: Cytokines and Monoclonal AntibodiesLokesh K. Jha*, Sandeep Mukherjee†, , 
 
 
 
doi:10.1016/bs.seda.2015.08.006
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Anti-TNF therapy: past, present and future

Anti-TNF therapy: past, present and future | Immunology and Biotherapies | Scoop.it
Abstract

While for a century therapeutics has been dominated by small molecules, i.e. organic chemicals of ~400Da absorbable via the gut, this is no longer the case. There are now a plethora of important medicines which are proteins and injectable, which have dramatically improved the therapy of many inflammatory diseases and of cancer. Most of these are monoclonal antibodies, some are receptor Ig Fc fusion proteins, others are cytokines or enzymes. The key to this new aspect of therapeutics has been the filling of unmet needs, and the consequent commercial success, which promoted further research and development. The first ‘biologic’ for a common disease, rheumatoid arthritis (RA), was a monoclonal antibody, infliximab, to human tumour necrosis factor (TNF). This was based on our work, which is described in this review, summarizing how TNF was defined as a good target in RA, how it was developed is described here, as well as future indications for anti-TNF and related agents. Biologics are now the fastest growing sector of therapeutics.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 3, 2015 5:52 PM
Claudia Monaco, Jagdeep Nanchahal, Peter Taylor, and Marc FeldmannAnti-TNF therapy: past, present and future

Int. Immunol. (2015) 27 (1): 55-62 doi:10.1093/intimm/dxu102

Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Best Selling Monoclonal Antibodies 2013

Best Selling Monoclonal Antibodies 2013 | Immunology and Biotherapies | Scoop.it

Via Krishan Maggon
Gilbert C FAURE's insight:

impressive for immunologists so far away from so big amounts of money

more...
Krishan Maggon 's curator insight, January 6, 2014 1:38 PM

Abstract

 

A review of the best selling monoclonal antibodies in 2013 and 2012 is provided. Humira with sales of over $11 billion ($9.3 billion in 2012) remains the best selling monoclonal antibody, biologic as well prescription drug brand in 2013 as in 2012. The ranks of the next 4 top selling mabs remained unchanged from the 2012 Table.  Remicade (9.7 Bn), Rituxan (7.5 Bn) , Herceptin (6.5 Bn) and Avastin (6.5 Bn) were the second, third, fourth and fifth top selling mabs in 2013. The actual sales for 2013 as reported by the companies are provided. The total sales of the top selling blockbuster mabs were $63 billion in 2013. The actual global sales of all the approved blockbuster sales or potential (sales >1 billion) monoclonal antibodies in 2013 is provided. Besides the top 5 mabs, there were 2 other monoclonal antibodies with sales of over 2 billion dollars and 5 with sales of over $ 1 billion in 2013. In addition 5 recently launched mabs were nearing to reach sales of $ 1 billion this year. Currently 30 monoclonal antibodies are marketed in the US and Europe (January 2014).  Alexion Soliris was the most expansive marketed monoclonal antibody with a price tag of $440,000 per year of treatment, a sort of Rolls-Royce of mabs.

 

Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed - Gisbert - 2015 - Alimentary Pharma...

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed - Gisbert - 2015 - Alimentary Pharma... | Immunology and Biotherapies | Scoop.it
SummaryBackground

One-third of patients with Crohn's disease (CD) or ulcerative colitis (UC) receiving anti-TNFs do not respond to treatment, and a relevant proportion experience loss of response or intolerance.

Aim

To investigate the efficacy and safety of a second anti-TNF agent after primary/secondary failure or intolerance to a first drug.

Methods

Inclusion criteria: studies evaluating the efficacy of infliximab (IFX), adalimumab (ADA) and certolizumab-pegol (CZP) as the second anti-TNF in CD or UC. Search strategy: Bibliographical searches (PubMed/Embase). Data synthesis: percentage of response/remission; the meta-analysis was performed using the inverse variance method.

Results

We included 46 studies (37 CD, 8 UC, 1 pouchitis). The CD studies comprised 32 switching IFXADA, 4 IFXCZP and 1 ADAIFX. Overall, the second anti-TNF after the failure of IFX in CD induced remission in 43% and response in 63% of patients. The remission rate was higher when the reason to withdraw the first anti-TNF was intolerance (61%) than after secondary (45%) or primary failure (30%); response rates were, respectively, 72%, 62% and 53%. All UC studies switched IFXADA, six of them reporting remission rates ranging from 0% to 50%. Adverse events rate ranged from 0% to 81% in CD, most of them mild (serious adverse event 0–21%, discontinuation rate <20%).

Conclusions

The efficacy of a second anti-TNF in CD patients largely depends on the cause for switching. The remission rate is higher when the reason to withdraw the first anti-TNF is intolerance (61%), compared with secondary (45%) or primary failure (30%). Further studies of switch ADAIFX are needed to evaluate this strategy. PROSPERO-registry-number: CRD42014012943.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 5, 2015 8:33 AM
Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failedJ. P. Gisbert1,2,*, A. C. Marín1,2, A. G. McNicholl1,2 andM. Chaparro1,2

Article first published online: 4 FEB 2015

DOI: 10.1111/apt.13083

© 2015 John Wiley & Sons Ltd

Issue

Alimentary Pharmacology & Therapeutics

Volume 41, Issue 7, pages 613–623, April 2015

Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Physicochemical characterization of Remsima®

Physicochemical characterization of Remsima® | Immunology and Biotherapies | Scoop.it
(2014). Physicochemical characterization of Remsima®. mAbs: Vol. 6, No. 5, pp. 1163-1177. doi: 10.4161/mabs.32221

Via Krishan Maggon
Gilbert C FAURE's insight:

first biosimilar

more...
Krishan Maggon 's curator insight, December 19, 2014 11:43 AM
mAbsVolume 6, Issue 5, 2014 Physicochemical characterization of Remsima® View full textDownload full textOpen accessDOI:10.4161/mabs.32221Soon Kwan Junga, Kyoung Hoon Leea, Jae Won Jeona, Joon Won Leea, Byoung Oh Kwona, Yeon Jung Kima, Jin Soo Baea, Dong-Il Kimb, Soo Young Leea & Shin Jae Changa*

pages 1163-1177

Publishing models and article dates explainedReceived: 30 Jun 2014Accepted: 30 Jul 2014Accepted author version posted online: 01 Nov 2014
Published online: 01 Sep 2014Article Views: 1197  http://www.celltrionhealthcare.com/remsima/com/